Scientia Pharmaceutica

Over the last decade, additive manufacturing (AM) has been widely investigated for developing on-demand, patient-centric, and personalized medications. Among various AM techniques, fused deposition modeling (FDM), semi-solid extrusion (SSE), inkjet printing, binder jet printing, stereolithography (SLA), and selective laser sintering (SLS) have been most widely studied for developing simple and complex pharmaceutical medications. Implementing the AM platform enables decentralized manufacturing of medications at the hospitals and clinical sites. The dose and release profiles of the dosage forms can be tailored based on patient needs, providing flexibility to the physician. In fact, streamlining the AM process into a continuous manufacturing process equipped with process analytical technology (PAT) tools will ensure the manufacturing and delivery of safe and efficacious medications to the patient population. Complex medications, such as polypills, which are complex and time-consuming to manufacture using traditional manufacturing techniques, can be printed quickly using the AM approach. The pediatric patient population can be attracted to medication by printing the dosage forms with a geometry of interest. The AM platform can be integrated with artificial intelligence (AI) and health records to accelerate drug development and tailor medications based on patient conditions. Despite the various advantages that the AM platform brings to the pharmaceutical field, a few limitations, such as scalability, material innovation, secondary processing, and regulatory evolution, need to be addressed. This review article compares the advantages and limitations of the existing AM techniques along with a note on the recent advancements and future perspectives.

In this study, a terminological and grammatical survey of essential and fatty oils of plant origin was performed in the selected Austrian, Hungarian, Spanish, and Belgian pharmacopoeias from the 18th to 19th centuries. The Latin-language prescriptions were analysed for their content, sections, and indications, and then translated from Latin into English, and supplemented with the source plants. Oil types were categorised based on their preparation and origin. Most oils belong to essential oils in Ph. Austriaca I–IV, Ph. Belgica, and Ph. Hungarica I (20 in each). Cooked oils are described as having the highest number in Ph. Hispanica (21), while pressed oils are also included in a high ratio in Ph. Hisp. (18) and Ph. Austriaca V (15). At the same time, those from minerals are described only in Ph. Belg. (2) and Ph. Hisp. (5). Latin terms are used in preparation methods, including the most concise descriptions in Ph. Austriaca V and Ph. Hg. I. This comprehensive study provides new linguistic data on the oils of herbs in the selected pharmacopoeias. Studies of essential oils have recently been progressing, and this analysis might help in understanding information from old pharmacopoeias.

Biopharmaceuticals are medical drugs produced by means of biotechnology. In contrast with small-molecule (traditional) drugs, which are usually synthesized chemically, biopharmaceuticals are derived from biological sources, including tissues, cells, or microorganisms. Biopharmaceuticals comprise a wide extent of therapies, such as vaccines, monoclonal antibodies, cell therapies, recombinant proteins, and gene therapies, as well as biosimilars. These products are designed to become important treatment options for different diseases, including cancer, autoimmune pathological disorders, andinfectious diseases. The development of biopharmaceuticals often includes multifaceted processes, involving genetic engineering and cellular culture techniques, to guarantee efficacy and safety. Accordingly, biopharmaceuticals’ legislation is a key component for ensuring the highest quality of medical products, as well as protecting public health. As a rapidly developing area inside the pharmaceutical industry, biopharmaceuticals represent a significant advancing stage in modern medicine, offering targeted therapies that can improve patient outcomes. Accordingly, this paper seeks to provide current state-of-the-art didactic information, including better insight into various challenges related to biopharmaceuticals’ development, classification, medical use, legislation and ethics.